Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010417 | 0.88 | USP2 (0.67) | USP2L3MBTL1MAPTABCB1HPGD | |
| SCHEMBL27352387 | 0.87 | NLRP3 (0.55) | USP2L3MBTL1MAPTABCB1NLRP3 | |
| SCHEMBL3258674 | 0.86 | L3MBTL1 (0.57) | USP2L3MBTL1MAPTTDP1ABCB1 | |
| SCHEMBL28327633 | 0.84 | L3MBTL1 (0.71) | L3MBTL1MAPTTDP1HPGDSMN1; SMN2 | |
| SCHEMBL11825493 | 0.84 | GLA (0.68) | USP2L3MBTL1MAPTABCB1HPGD | |
| SCHEMBL5000478 | 0.83 | LMNA (0.62) | L3MBTL1MAPTTDP1HPGDSMN1; SMN2 | |
| SCHEMBL2871937 | 0.83 | MAPT (0.62) | USP2MAPTTDP1ABCB1HPGD | |
| SCHEMBL28851259 | 0.83 | L3MBTL1 (0.67) | L3MBTL1MAPTTDP1HPGDSMN1; SMN2 | |
| SCHEMBL31562911 | 0.82 | USP2 (0.51) | USP2MAPTTDP1ABCB1NLRP3 | |
| SCHEMBL20150685 | 0.82 | ABCB1 (0.64) | USP2L3MBTL1MAPTABCB1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-7741493-B2 | 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease | AVENTIS PHARMACEUTICALS INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1651613-B1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMA INC (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009085256-A1 | ANTI-HIV COMPOUNDS | PANACOS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ARTESIAN THERAPEUTICS, INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ARTESIAN THERAPEUTICS, INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ARTESIAN THERAPEUTICS, INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20040242648-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
| CN-1507442-A | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors | — | 2004-06-23 | — | — | CN | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004033444-A1 | DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY | ARTESIAN THERAPEUTICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-4914093-A | CARDIOVASCULAR DISORDERS | SANKYO COMPANY LIMITED (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0330242-A1 | Pyridazinone derivatives, their preparation and use | Sankyo Company Limited (JP) | 1989-08-30 | — | — | EP | disclosed |
| EP-0178189-A2 | Pyridazinone derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| US-4117014-A | PROSTAGLANDIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1978-09-26 | — | — | US | disclosed |
| US-3985791-A | 16-Phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives | SYNTEX (U.S.A.) INC. (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | USP2 4581/4885L3MBTL1 4640/4885MAPT 4727/4885 |
| US-20040242648-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | CACNA1C, PDE3A, PDE3B | USP2 3426/4885L3MBTL1 3685/4885MAPT 2452/4885 |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ADRB2, ADRB3, ADRB1 | USP2 1806/4885L3MBTL1 3584/4885MAPT 4285/4885 |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | P2RX3, P2RX2, P2RX5 | USP2 4540/4885L3MBTL1 4692/4885MAPT 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.